There are many domestic targeted drugs for lung cancer, and the common ones are Gefitinib, Amitinib Mesylate, etc. In addition, Erlotinib, Ectinib, etc. are also included in the list. In addition, domestic targeted drugs also include erlotinib, ectinib, etc. Patients are advised to follow the doctor’s instruction to use the drugs. 1. Gefitinib: Gefitinib can inhibit the epidermal growth factor receptor-dependent cell proliferation of tumor cells, so as to inhibit tumor growth and metastasis. It is usually used for locally advanced metastatic non-small-cell lung cancer that fails chemotherapy with therapeutic agents of class I and class II paclitaxel, and adverse reactions such as diarrhea, nausea, and vomiting may appear after using the drug, and it cannot be used by the patients who are allergic to the components of this product. 2. Ametinib mesylate: this drug is usually used for locally advanced or metastatic non-small cell lung cancer with disease progression during or after previous treatment with epidermal growth factor receptor tyrosine kinase inhibitor and the presence of EGFR T790M mutation positivity is confirmed by test, adverse reactions such as skin rash and stomatitis may occur after using the drug, and it is forbidden to use for patients who are allergic to the ingredients of this product. 3. Erlotinib: Single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with sensitive mutations in the epidermal growth factor receptor (EGFR) gene. This includes first-line therapy, maintenance therapy, or second-line and above therapy after at least one prior progression to chemotherapy. 4. ectinib: This single agent is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with sensitive mutations in the epidermal growth factor receptor (EGFR) gene. In addition, it may be tried for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure of at least one prior chemotherapy regimen, with prior chemotherapy primarily referring to platinum-based combination chemotherapy.